ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Sponsor: Acepodia Biotech, Inc.
This PHASE1 trial investigates HER2-positive Gastric Cancer and HER2-positive Metastatic Breast Cancer and is currently completed. Acepodia Biotech, Inc. leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jul 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Acepodia Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .